August 30, 2021
MELBOURNE (August 30, 2021) – SYNthesis Research (“SYNthesis”) has today announced that Dr Martine Keenan will be joining as Chief Innovation Officer. Martine brings to the role exceptional national and international experience in translational drug discovery & development, and the reputation of being a respected and accomplished executive. Martine’s areas of expertise include medicinal chemistry, pre-clinical drug development, IP development, project management, research commercialisation and stakeholder engagement.
Martine previously spent 13 years at Epichem Pty Ltd, Australia, where she held multiple positions during her tenure including Chief Scientific Officer and Executive Director, and at Eli Lilly, UK.
SYNthesis CEO Fabio Turatti said “With our new-found confidence in working remotely and flexibly, SYNthesis Research widened its recruitment search to find Martine Keenan for the role of Chief Innovation Offer. Martine’s experience and expertise is unique in the sector, and we are thrilled to have her join our growing team of experts”.
Welcome aboard Martine!
About SYNthesis Research
SYNthesis Research is a preclinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including cancer, chronic inflammatory conditions and life-threatening infections, amongst others. SYNthesis is creating a diversified pipeline through the expertise of its research, development and management team and its extensive network of scientists, clinicians and industry leaders. This pipeline, advanced both internally and through SYNthesis’ investee entities, is comprised of 5 product candidates, including 3 entering formal IND-enabling studies.